PDT Partners’s Vir Biotechnology VIR Stock Holding History

PDT Partners’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-220,821	Closed	-$1.65M	–	843
2024 Q3	$1.65M	Buy	220,821 +56,494	+34%	+$491K	0.15%	259
2024 Q2	$1.46M	Buy	+164,327	New	+$1.58M	0.14%	267

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

PDT Partners's VIR Position: Q4 2024 in Review

PDT Partners sold out of Vir Biotechnology (VIR) in Q4 2024, closing a stake of 220,821 shares — an estimated $1.65M sold.

PDT Partners first reported a position in VIR in Q2 2024 and held it in 2 quarters. The position peaked at $1.65M in Q3 2024. 208 funds tracked by Wall St. Rank hold VIR as of Q4 2024.

PDT Partners reported no remaining Vir Biotechnology position as of Q4 2024 after selling out during the quarter.
PDT Partners sold 220,821 Vir Biotechnology shares in Q4 2024, an estimated $1.65M.
PDT Partners first reported a position in Vir Biotechnology in Q2 2024 and held it in 2 quarters.
PDT Partners's Vir Biotechnology position peaked at $1.65M in Q3 2024.
208 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2024.

Based on PDT Partners's 13F filing for Q4 2024, filed 14 Feb 2025.